DC cell-based hepatitis B virus T epitope peptide

A hepatitis B virus and epitope peptide technology, applied in the fields of genetic engineering, biomedicine, and protein engineering, can solve the problems of not being able to cure hepatitis B or other complications, or effectively blocking liver fibrosis and sclerosis, etc., to achieve the elimination of viruses in the body, Effect of blocking liver fibrosis and cirrhosis and improving clinical symptoms

Inactive Publication Date: 2015-03-04
阎平希 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta transmits to the fetus and blocks the transmission of hepatitis B virus to breastfed newborns through milk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DC cell-based hepatitis B virus T epitope peptide
  • DC cell-based hepatitis B virus T epitope peptide
  • DC cell-based hepatitis B virus T epitope peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The DC cell-based hepatitis B virus T epitope peptide of the present invention has an amino acid sequence of QLFHLCLII and a molecular weight of 1150.

[0023] The epitope peptide was synthesized using the standard Fmoc protocol, and after purification by HPLC, its purity was greater than 98%, see figure 1 , mass spectrometry and confirmed its molecular weight in line with the theoretical value.

[0024] The synthesis method of the hepatitis B virus T epitope peptide based on DC cells of the present invention is:

[0025] 1. Design and screening of epitope peptides

[0026] 1. Hepatitis B virus antigen

[0027] 乙型病毒抗原的核心抗原为乙肝病毒在体内引起CTL反应的主要抗原,核苷酸序列为639bp,编码蛋白为212氨基酸,MQLFHLCLIISCSCPTVQASKLCLGWLWGMDIDPYKEFGASVELLSFLPSDFFPSIRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMNLATWVGSNLEDPASRELVVSYVNVNMGLKIRQLLWFHISCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSRESQC.Genebank[DQ448622];来源于中国人群genotype B,血清学分型adw2 . .

[0028] 2. Homology analysis

[0029...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of protein engineering, gene engineering and biomedicine, and particularly relates to a DC cell-based hepatitis B virus T epitope peptide. According to the technical scheme, the DC cell-based hepatitis B virus T epitope peptide is characterized by consisting of 9 amino acid residues with an amino acid sequence of QLFHLCLII. According to the DC cell-based hepatitis B virus T epitope peptide, basic amino acid is used as a framework, a solid-phase synthesis technology is adopted, a same preset amino acid sequence is simultaneously synthesized on the framework; with the hepatitis B virus as a design target, and the DC cell-based hepatitis B virus specific epitope peptide is produced by adopting a synthesis technology; the epitope peptide is loaded in-vitro on the DC cell, the mature DC cell is infused into bodies of specific people, and generation of the specificity is capable of eliminating the hurt caused by hepatitis B virus infection and particularly cleaning viruses in the body and improving the clinical syndromes against acute hepatitis B.

Description

[0001] This application is a divisional application with an application date of March 25, 2011, an application number of 201110073862.3, and an invention title of "A Hepatitis B Virus T Epitope Peptide Based on DC Cells". technical field [0002] The invention relates to the fields of protein engineering, genetic engineering and biomedicine, in particular to a DC cell-based hepatitis B virus T epitope peptide. Background technique [0003] Worldwide, more than 400 million people are infected with the hepatitis B virus, and 1 million people die each year from complications of the infection, including cirrhosis, hepatocellular carcinoma, or other complications. Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61P31/20A61P1/16
Inventor 罗进闫小君
Owner 阎平希
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap